본문 바로가기
KERD
논문KCI 등재

국내외 이상지질혈증 치료지침의 비교 및 한국인에서의 치료지침의 적절성

The Comparison of Guidelines for Management of Dyslipidemia and the Appropriateness of Them in Korea

박병주|송홍지|조영규
대한가정의학회 (The Korean Academy Of Family Medicine)|2010.03|Korean Journal of Family Medicine|제31권 제3호|pp. 171-181

2

조회

0

다운로드

11

인용

0

참고문헌

키워드

이상지질혈증; 치료지침; 심혈관질환; 역학; 지질저하제; 스타틴Dyslipidemia; Guideline; Cardiovascular Disease; Epidemiology; Lipid-Lowering Agent; Statin
주제분류가정의학

초록

이상지질혈증이 심혈관질환의 중요한 위험인자이며, 혈중 지질 농도의 개선을 통해 심혈관질환을 예방할 수 있다는 사실이 밝혀지면서, 미국을 비롯한 세계의 여러 나라에서 이상지질혈증의 개선을 통해 심혈관질환을 예방하기 위한 근거 중심 치료지침들을 발표하고 있다. 우리나라에서도 한국지질동맥경화학회를 중심으로 이상지질혈증 치료지침을 발표하였으나, 치료지침을 구체화할 만한 한국인을 대상으로 한 연구결과가 부족하여, 외국의 치료지침을 참고하여 전문가들의 의견을 모아 치료기준을 정하고 있다. 외국의 치료지침을우리나라에 적용하기 위해서는 우리나라의 질병 발생양상 및의료환경 등을 먼저 고려해야 한다. 이에 우리나라의 심혈관질환의 역학적 특성을 검토하여 국내외의 이상지질혈증 치료지침들이 한국인에게 적절한지를 평가하였으며, 이와 함께건강보험심사평가원의 지질저하제 처방 심사기준의 문제점에 대해서 살펴보았다.

Abstract

There have been accumulating evidences that dyslipidemia is a major risk factor of cardiovascular disease (CVD) and improvement in lipid profile can reduce the incidence of CVD. Guidelines for management of dyslipidemia have been developed by major organizations in several contries including the United States. In Korea, a guideline was also published by the Korean Society of Lipidology and Atherosclerosis. However, This guideline was not based on evidences in Korea,but was made by a consensus of experts using a pre-developed guideline as a reference. For clinical application for Korean of guidelines developed in different nations, the disease epidemiology and medical environment in Korea should be considered. In this article, we reviewed whether guidelines for management of dyslipidemia are applicable in Korean context.

참고문헌 (41)

  1. Park BJ, "Evidence-based healthcare. 1st ed" (2009), Korea Medical Publisher
  2. Committee for Establishing Treatment Instruction for Dyslipidemia of the Korean Society of Lipidology and Atherosclerosis, "Guidelines for management of dyslipidemia. 2nd ed" (2009), Korean Society of Lipidology and Atherosclerosis
  3. Schunemann HJ, "Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation", Health Res Policy Syst, 4, pp.25~ (2006)
  4. Korea Centers for Disease Control and Prevention, "The Third Korea National Health and Nutrition Examination Survey (KHANES III)", Korea Centers for Disease Control and Prevention, ~ (2007)
  5. Carroll MD, "Trends in serum lipids and lipoproteins of adults, 1960-2002", JAMA, 294, pp.1773~1781 (2005)
  6. Korea Centers for Disease Control and Prevention, "The Fourth Korea National Health and Nutrition Examination Survey (KHANES IV-1), 2007", Korea Centers for Disease Control and Prevention, ~ (2008)
  7. World Health Organization, "The global burden of disease: 2004 update", World Health Organization, ~ (2008)
  8. Korea National Statistical Oce, "Annual report on the cause of death statistics, 2007", 2008, ~ (2007)
  9. Lee BC, "Epidemiology of stroke in Korea", J Korean Med Assoc, 45, pp.1415~1421 (2002)
  10. Suh I, "Cardiovascular mortality in Korea: a country experiencing epidemiologic transition", Acta Cardiol, 56, pp.75~81 (2001)
  11. Suh I, "Epidemiology of coronary heart disease", Hanyang Med Rev, 26, pp.11~15 (2006)
  12. Brownson RC, "Chronic disease epidemiology and control. 2nd ed" (1998), American Public Health Association
  13. Jee SH, "Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study", JAMA, 282, pp.2149~2155 (1999)
  14. "Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: the Expert Panel", Arch Intern Med, 148, pp.36~69 (1988)
  15. "Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)", JAMA, 269, pp.3015~3023 (1993)
  16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
  17. Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines", Circulation, 110, pp.227~239 (2004)
  18. "National Heart Lung and Blood Institute. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel IV)"[URL]
  19. LaRosa JC, "Past, present, and future standards for management of dyslipidemia", Am J Med, 116(6A), pp.3~8 (2004)
  20. Fodor JG, "Recommendations for the management and treatment of dyslipidemia: report of the Working Group on Hypercholesterolemia and Other Dyslipidemias", CMAJ, 162, pp.1441~1447 (2000)
  21. Genest J, "Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update", CMAJ, 169, pp.921~924 (2003)
  22. McPherson R, "Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-- recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease", Can J Cardiol, 22, pp.913~927 (2006)
  23. Genest J, "2009 Canadian Cardiovascular Society", Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations, 2009, pp.25, 567~579
  24. Pyorala K, "Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension", Atherosclerosis, 110, pp.121~161 (1994)
  25. Prevention of coronary heart disease in clinical practice, "Recommendations of the Second Joint Task Force of European and other societies on coronary prevention", Eur Heart J, 19, pp.1434~1503 (1998)
  26. De Backer G, "European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)", Eur J Cardiovasc Prev Rehabil, 10, pp.1~10 (2003)
  27. Graham I, "European guidelines on cardiovascular disease prevention in clinical practice: executive summary", Atherosclerosis, 194, pp.1~45 (2007)
  28. Teramoto T, "Executive summary of Japan Atherosclerosis Society ( JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese", J Atheroscler Thromb, 14, pp.45~50 (2007)
  29. Koba S, "Treatment of hyperlipidemia from Japanese evidence", J Atheroscler Thromb, 13, pp.267~280 (2006)
  30. Okamura T, "The relationship between serum total cholesterol and all-cause or cause-specic mortality in a 17.3-year study of a Japanese cohort", Atherosclerosis, 190, pp.216~223 (2007)
  31. Kim SH, "Recent trend of management of hyperlipidemia and achievement of lipid treatment goals", J Korean Acad Fam Med, 26(11), pp.450~457 (2005)
  32. Jee SH, "Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea", J Korean Soc Lipidol Atheroscler, 14, pp.153~168 (2004)
  33. Vergouwen MD, "Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease", Stroke, 39, pp.497~502 (2008)
  34. Wang A, "Ile118Val genetic polymorphism of CYP3A4 and its eects on lipid-lowering ecacy of simvastatin in Chinese hyperlipidemic patients", Eur J Clin Pharmacol, 60, pp.843~848 (2005)
  35. Liao JK, "Safety and efficacy of statins in Asians", Am J Cardiol, 99, pp.410~414 (2007)
  36. "Crestor (rosuvastatin calcium) Prescribing Information"[URL]
  37. 한기훈, "고지혈증의 유형에 따른 치료", 대한의사협회지, 52(3), pp.299~311 (2009), 대한의사협회
  38. Kim CJ, "Hypercholesterolemia: management of Korean patients in new millennium", Korean J Med, 72, pp.580~592 (2007)
  39. 김상현, "국내 병의원의 고콜레스테롤혈증 치료 현황", Korean Circulation Journal, 36(8), pp.593~599 (2006), 대한심장학회
  40. 성지동, "국내 10개 대학병원의 관동맥질환자의 고콜레스테롤혈증 치료 현황", 대한내과학회지, 69(4), pp.371~378 (2005), 대한내과학회
  41. Kim SH, "Perspective for improvement in the treatment of dyslipidemia in Korea", J Korean Soc Lipidol Atheroscler, 19, pp.155~160 (2009)

관련 논문AI추천

이상지질혈증의 국내 및 국외 치료 가이드라인 비교이송, 김주영, 이경은, 최윤정한국임상약학회 · 한국임상약학회지2017 · 제27권 제4호Dyslipidemia Fact Sheet in Korea, 2022강신애, 김현창, 배재현, 원종철, 이호규, 정인경, 진흥용, Eun-Sun Jin, Jee-Seon Shim, Jenny Moon, Shin Min-Jeong, Sung Eun Kim한국지질동맥경화학회 · 지질·동맥경화학회지2023 · 제12권 제3호Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea송우혁, 이상학, 장양수, 전동운, 정명호, 정원주, 허승호, Ami Vyas, Anselm K Gitt, Baishali Ambegaonkar, Dominik Lautsch, Martin Horack, Philippe Brudi한국지질동맥경화학회 · 지질·동맥경화학회지2019 · 제8권 제2호Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data김현창, 백종민, 이혁희, 이호규, 조소미, 주형준, 허지은, 홍순준, Korean Society of Lipidology and Atherosclerosis (KSoLA) Public Relations Committee한국지질동맥경화학회 · 지질·동맥경화학회지2021 · 제10권 제2호국내 성인환자에서 죽상동맥경화성 심혈관질환 위험도와 스타틴 처방 현황김종윤, 유기연한국임상약학회 · 한국임상약학회지2021 · 제31권 제3호2018 Guidelines for the Management of Dyslipidemia in Korea김병진, 김은미, 김재현, 김현창, 김혜진, 나진오, 노정현, 문민경, 박광열, 송윤주, 오미선, 이경희, 이상학, 이은영, 이은정, 임정현, 정인경, 최성훈, 한상엽, 홍순철한국지질동맥경화학회 · 지질·동맥경화학회지2019 · 제8권 제2호

이 간행물의 다른 논문 (5건)

사회성 기술 향상을 위한 다차원적 프로그램이 노인성치매환자에 미치는 효과에 대한 예비연구박훈기, 유정현, 고관홍, 채희중, 황환식pp. 182-189체성분 분석기 InBody 720로 측정한 내장지방 면적과 다양한 복부비만 측정법 간의 연관성이선영, 김동관, 이은지, 김규남, 유선미pp. 190-197성인 남성에서 대사증후군 진단도구별 유병률과 관상동맥질환 발생위험도이건호, 김성희, 박순우, 김종연, 이혜미, 서혁수pp. 198-207한국남자에서 결혼상태와 대사증후군과의 관련성김문찬, 최정헌, 김창섭, 정태흠pp. 208-214한국 기혼 여성의 명절 스트레스: 검진센터 방문여성을 중심으로정진규, 박한주, 김종성, 정숙영, 강동수, 최상욱, 김성수, 임철순pp. 215-221
원문 보기